Evidence map›Paper›PMID 37185210›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2023

Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement.

Aly-Khan A Lalani, Anil Kapoor, Naveen S Basappa, Bimal Bhindi, Georg A Bjarnason, Dominick Bosse, Rodney H Breau, Christina M Canil, Luisa M Cardenas, Vincent Castonguay and 14 more

Erratum issuedOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Case series - Laparoscopic radical nephrectomy for kidney cancer in pregnancy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025
    Article
  2. Article
  3. Review
  4. 2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024
    Article
  5. Review
  6. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2024
    Review
  7. Advances in the management of renal cell carcinoma.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 15 institutions in 3 countries.

Aly-Khan A LalaniDepartment of Medical Oncology, Juravinski Cancer Centre, McMaster, Hamilton, ON, Canada.
Anil KapoorSt Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada.
Naveen S BasappaDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Bimal BhindiSouthern Alberta Institute of Urology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Georg A BjarnasonOdette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Dominick BosseDivision of Medical Oncology, University of Ottawa, Ottawa, ON, Canada.
Rodney H BreauDepartment of Surgery, University of Ottawa, Ottawa, ON, Canada.
Christina M CanilDivision of Medical Oncology, University of Ottawa, Ottawa, ON, Canada.
Luisa M CardenasDepartment of Medical Oncology, Juravinski Cancer Centre, McMaster, Hamilton, ON, Canada.
Vincent CastonguayCentre de recherche du Centre Hospitalier Universitaire de Québec - Université Laval (CRCHUQc-UL), Centre de recherche sur le cancer (CRC) de l'Université Laval, Québec, QC, Canada.
Claudia Chavez-MunozVancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
William ChuOdette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Shaan DudaniDepartment of Oncology, William Osler Health System, Brampton, ON, Canada.
Jeffrey GrahamUniversity of Manitoba, Winnipeg, MB, Canada.
Daniel Y C HengDepartment of Medical Oncology, Tom Baker Cancer Center, Calgary, AB, Canada.
Christian KollmannsbergerBC Cancer - Vancouver Centre, Vancouver, BC, Canada.
Jean-Baptiste LattoufDepartment of Surgery, University of Montreal, Montreal, QC, Canada.
Scott MorganDepartment of Radiation Oncology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
M Neil ReaumeDivision of Medical Oncology, University of Ottawa, Ottawa, ON, Canada.
Patrick O RichardDepartment of Urology, Centre Hospitalier Universitaire de Sherbrooke and Centre de Recherche du CHUS, Sherbrooke, QC, Canada.
Anand SwaminathDepartment of Radiation Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
Simon TanguayDivision of Urology, Department of Surgery, McGill University, Montreal, QC, Canada.
Lori A WoodDivision of Medical Oncology, Dalhousie University, Halifax, NS, Canada.
Luke T LavalléeDivision of Urology and Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
University of Ottawa · CAJuravinski Cancer Centre · CASunnybrook Health Science Centre · CACentre hospitalier universitaire de Québec · CACentre Hospitalier Universitaire de Sherbrooke · CADalhousie University · CAMcGill University · CAOttawa Hospital · CASt. Joseph’s Healthcare Hamilton · CAUniversité de Montréal · CAUniversity of Alberta · CAUniversity of British Columbia · CAUniversity of Calgary · CAUniversity of Manitoba · CAWilliam Osler Health System · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSeveral recent randomized trials evaluated the impact of adjuvant immune checkpoint inhibitor (ICI)-based therapy on post-surgical outcomes in renal cell carcinoma (RCC), with disparate results. The objective of this consensus statement is to provide data-driven guidance regarding the use of ICIs after complete resection of clear-cell RCC in a Canadian context.

methodsAn expert panel of genitourinary medical oncologists, urologic oncologists, and radiation oncologists with expertise in RCC management was convened in a dedicated session during the 2022 Canadian Kidney Cancer Forum in Toronto, Canada. Topic statements on the management of patients after surgery for RCC, including counselling, risk stratification, indications for medical oncology referral, appropriate followup, eligibility and management for adjuvant ICIs, as well as treatment options for patients with recurrence who received adjuvant immunotherapy, were discussed. Participants were asked to vote if they agreed or disagreed with each statement. Consensus was achieved if greater than 75% of participants agreed with the topic statement.

resultsA total of 22 RCC experts voted on 14 statements. Consensus was achieved on all topic statements. The panel felt patients with clear-cell RCC at increased risk of recurrence after surgery, as per the Keynote-564 group definitions, should be counselled about recurrence risk by a urologist, should be informed about the potential role of adjuvant ICI systemic therapy, and be offered referral to discuss risks and benefits with a medical oncologist. The panel felt that one year of pembrolizumab is currently the only regimen that should be considered if adjuvant therapy is selected. Panelists emphasized current opinions are based on disease-free survival given the available results. Significant uncertainty regarding the benefit and harms of adjuvant therapy remains, primarily due to a lack of consistent benefit observed across similar trials of adjuvant ICI-based therapies and immature overall survival (OS) data.

conclusionsThis consensus document provides guidance from Canadian RCC experts regarding the potential role of ICI-based adjuvant systemic therapy after surgery. This rapidly evolving field requires frequent evidence-based re-evaluation.

Identifiers

PMID37185210
PMCPMC10132379
OpenAlexW4367052200

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.